Disease Evolution in Women With Highly Active MS Who Suspended Natalizumab During Pregnancy vs Rituximab/Ocrelizumab Before Conception-Reference-Cited by-同舟云学术

Disease Evolution in Women With Highly Active MS Who Suspended Natalizumab During Pregnancy vs Rituximab/Ocrelizumab Before Conception

Published:2023-09 Issue:5 Volume:10 Page:
ISSN:2332-7812
Container-title:Neurology Neuroimmunology & Neuroinflammation
language:en
Short-container-title:Neurol Neuroimmunol Neuroinflamm

Author:

Demortiere Sarah¹^ORCID,Maarouf Adil¹^ORCID,Rico Audrey¹^ORCID,Boutiere Clemence¹^ORCID,Hilezian Frederic¹,Durozard Pierre¹^ORCID,Pelletier Jean¹,Audoin Bertrand¹^ORCID

Affiliation:

1. From the Department of Neurology (S.D., A.M., A.R., C.B., F.H., J.P., B.A.), CRMBM, APHM, Aix Marseille University; and Centre Hospitalier d'Ajaccio (P.D.), France.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical),Neurology

Link

https://www.neurology.org/doi/pdfdirect/10.1212/NXI.0000000000200161

Reference28 articles.

1. Treatment of multiple sclerosis — success from bench to bedside

2. Treatment of Women with Multiple Sclerosis Planning Pregnancy

3. Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis

4. Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy

5. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple Sklerose: Therapie bei Kinderwunsch und in der Schwangerschaft;Deutsches Ärzteblatt Online;2024-08-09

2. Post-Partum Clinical and Patient-Reported Outcome Changes in Mothers with Multiple Sclerosis: Findings from the NAPPREMS Study;Medicina;2024-07-18

3. Evidence of disease activity during pregnancy and post-partum in MS patients treated with high-efficacy therapies;Multiple Sclerosis and Related Disorders;2024-05

4. Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis;Neurology Neuroimmunology & Neuroinflammation;2024-05